Exhibit 10.20
EMPLOYMENT AGREEMENT
This Employment Agreement (this “Agreement”), entered into on May 2, 2018 and effective for employment as of May 15, 2018 (the “Effective Date”), is made by and between Pharmaceutical Product Development, LLC, a Delaware limited liability company (together with any successor thereto, the “Company”), and Christopher G. Scully (“Executive” and, together with the Company, the “Parties”) and, solely with respect to Sections 1(c), 2(h), 9(m) and 9(n), Eagle Holding Company I, a Delaware corporation (“Parent”). Where the context requires, references herein to the “Company” include Pharmaceutical Product Development, Inc., a North Carolina corporation and predecessor to the Company. For the avoidance of doubt, this Agreement is binding on the Company and Executive on the date it is fully executed by both parties.
RECITALS
WHEREAS, the Company previously provided Executive that certain Offer Letter, dated as of April 17, 2018 (the “Offer Letter”);
WHEREAS, in conjunction with the execution of this Agreement, the Parties will enter into a Proprietary Information and Inventions Agreement, attached hereto asExhibit A (as amended, supplemented, or otherwise modified from time to time, the “Proprietary Information Agreement”);
WHEREAS, the Parties desire that this Agreement replace and supersede the Offer Letter as provided herein; and
WHEREAS, Executive and the Company mutually desire that Executive provide services to the Company on the terms herein provided.
AGREEMENT
NOW, THEREFORE, in consideration of the foregoing and of the respective covenants and agreements set forth below, the Parties hereto agree as follows:
(a) General. The Company shall employ Executive and Executive shall enter the employ of the Company, for the period and in the position set forth in thisSection 1, and upon and subject to the other terms and conditions herein provided.
(b) Employment Term. The term of employment under this Agreement (the “Term”) shall be for the period beginning on the Effective Date and ending on December 31, 2021, subject to earlier termination as provided inSection 3. The Term shall automatically renew for additional one (1) year periods unless no later than sixty (60) days prior to the end of the otherwise applicable Term either Party gives written notice ofnon-extension of the Term to the other, in which case Executive’s employment will terminate at the end of the then applicable Term or any other date set by the Company in accordance withSection 3, subject to earlier termination as provided inSection 3.
(c) Position and Duties. During the Term, Executive shall serve as Executive Vice President and Chief Financial Officer of the Company and the Parent, report to the Chief Executive Officer of the Company and the Parent and have such customary responsibilities, duties and authority normally associated with such position and as may from time to time be assigned to Executive by the Chief Executive Officer of the Company or the Board (as defined below). Executive shall devote substantially